It might be also important to widen the screening for anti-IgLON5 antibodies to other neurological symptoms that may overlap with other more frequent neurodegenerative conditions, such as, e.g., PSP or ALS, particularly when these are associated with atypical symptoms [54] and likely also to a subset of TDP-43 proteinopathies. Here, IGLON5 is linked to proteostasis deficiencies.